Technology Transfer: our areas of expertise

Institut Curie applauds the dazzling success of its spin-off Emglev Therapeutics, acquired by Valerio Therapeutics

Just over a year after its creation, Emglev Therapeutics, an Institut Curie spin-off specializing in the development of next-generation antibodies for improved treatment of solid tumors, announces its acquisition by Valour Bio, a subsidiary of the listed company Valerio Therapeutics. Institut Curie salutes this remarkable achievement, which testifies to the quality of its innovations and the relevance of its incubation program, a source of disruptive technologies for the benefit of patients.

04/10/2024